Reliable Biopharmaceutical Corporation (RBC) Announces the Launch of cGMP HEPES Buffer

Share Article

Reliable Biopharmaceutical Corporation announces the launch of cGMP HEPES buffer to serve the biopharmaceutical industry.

cGMP HEPES Buffer is used in many critical processes by the biopharmaceutical industry. As regulations surrounding supply chain and excipient quality become more stringent, there is a need for high quality GMP commercial ingredient manufacturing. Reliable’s cGMP HEPES Buffer is manufactured following stringent cGMP guidelines in a newly constructed and qualified manufacturing suite at their US facility. “Reliable utilizes innovative validated processes, equipment, and analysis to manufacture the highest quality cGMP HEPES Buffer in the world,” said David Feldker, CEO and President of Reliable Biopharmaceutical Corporation.

RBC will be launching additional cGMP buffers over the next several months that conform to stringent standards. RBC offers cGMP HEPES in convenient prepackaged development quantities on their NEW Catalog site. RBC also offers a Reaction Ready™ service to deliver any customized quantity in any packaged configuration to help our customers reduce waste and improve ease of manufacturing.

About Reliable Biopharmaceutical Corporation
Founded in 1968, RBC is an integrated developer and manufacturer of Active Pharmaceutical Ingredients (APIs) and High Purity Ingredients (HPIs) for pharmaceuticals and biologics. RBC has established a strong position as a leading developer and manufacturer of complex generic injectable APIs, cGMP Buffers, and cGMP Processing Aids. The company has a number of DMFs that have been accepted by Regulatory Agencies and has more in various stages of development. RBC's APIs are in leading generic injectable drugs that treat cancer, heart disease, hypertension, anxiety and other serious and life threatening illnesses. RBC HPIs are critical processing aids for many of the world's leading pharmaceutical and biotechnology companies.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

James Wickenhauser
Reliable Biopharmaceutical Corp.

Visit website